Published: Fri, October 06, 2017
Worldwide | By Isabel Fisher

ProShare Advisors LLC Boosts Position in Global Blood Therapeutics, Inc. (GBT)

ProShare Advisors LLC Boosts Position in Global Blood Therapeutics, Inc. (GBT)

The main goal in developing of this indicator was reducing the lag between the indicator and price action by making it fast-acting and more sensitive to market changes. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold.

09/08/2015 - Goldman Sachs began new coverage on GLOBAL BLOOD THERAPEUTICS, INC. giving the company a "neutral" rating.

Other hedge funds have also made changes to their positions in the company. BNP Paribas Arbitrage SA now owns 4,547 shares of the company's stock valued at $124,000 after purchasing an additional 3,975 shares during the last quarter. Great West Life Assurance Co.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Monday, March 13th.

06/17/2016 - GLOBAL BLOOD THERAPEUTICS, INC. had its "buy" rating reiterated by analysts at Empire Asset Management. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of Global Blood Therapeutics in the first quarter worth about $230,000. Legal & General Group Plc lifted its stake in shares of Global Blood Therapeutics by 10.1% in the 1st quarter. The See Remarks now owns $4,297,650 of the stock per an SEC filing yesterday.

In other news, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction on Tuesday, July 25th.


Moving averages can help spot trends and price reversals. The company had a trading volume of 2,250,749 shares. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, September 29th. The disclosure for this sale can be found here. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Corporate insiders own 5.30% of the company's stock. BlackRock Inc. boosted its holdings in Global Blood Therapeutics by 30.0% in the 2nd quarter. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & worldwide copyright and trademark legislation.

The company reported its EPS on 6/29/2017. Needham & Company LLC started coverage on Global Blood Therapeutics in a research report on Wednesday, September 20th. The company has a consensus rating of "Buy" and an average target price of $55.70. BidaskClub downgraded Global Blood Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, August 11th.

Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Finally, ValuEngine upgraded Global Blood Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 10th.

On July 11 Morgan Stanley held the company rating at "Overweight" and lowered the price target to $51.00 from $67.00. The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.50. The company now has a consensus rating of "Buy" and a consensus price target of $52.27. (NASDAQ GBT) opened at 32.35 on Thursday. The company's 50 day moving average price is $28.25 and its 200 day moving average price is $29.67. The stock's market capitalization is 1.41B. The company rocked its 52-Week High of $41.15 and touched its 52-Week Low of $13.35.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Monday, August 7th. Analysts expect next quarter's EPS to be $-0.67 and the next full year EPS is anticipated to be $-2.91. During the same quarter in the prior year, the firm earned ($0.58) EPS. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GLOBAL BLOOD THERAPEUTICS, INC. with MarketBeat.com's FREE daily email newsletter.

Like this: